Standard Chem & Pharm CO., LTD. (1720.TW)
TWD 61.0
(-2.09%)
TWD 61.0
(-2.09%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -954.74 Million TWD | -6000.84% |
| 2022 | -11.61 Million TWD | 98.05% |
| 2021 | -594.47 Million TWD | -2486.26% |
| 2020 | -22.98 Million TWD | 88.07% |
| 2019 | -192.66 Million TWD | -436.68% |
| 2018 | -35.89 Million TWD | 16.96% |
| 2017 | -43.23 Million TWD | -21.48% |
| 2016 | -35.58 Million TWD | -43.76% |
| 2015 | -24.75 Million TWD | -123.84% |
| 2014 | 103.85 Million TWD | 206.35% |
| 2013 | -97.65 Million TWD | 66.06% |
| 2012 | -287.73 Million TWD | -143.93% |
| 2011 | -117.95 Million TWD | -231.53% |
| 2010 | 89.68 Million TWD | 121.77% |
| 2009 | -411.97 Million TWD | -10.46% |
| 2008 | -372.96 Million TWD | -844.65% |
| 2007 | -39.48 Million TWD | -155.6% |
| 2006 | 71 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -403.23 Million TWD | -20.36% |
| 2024 Q2 | -445.63 Million TWD | -10.51% |
| 2023 Q4 | -335.01 Million TWD | -2310.37% |
| 2023 FY | -335.01 Million TWD | -2783.35% |
| 2023 Q1 | -199.6 Million TWD | -1617.91% |
| 2023 Q2 | -434.07 Million TWD | -117.47% |
| 2023 Q3 | -13.89 Million TWD | 96.8% |
| 2022 Q2 | -48.85 Million TWD | 90.96% |
| 2022 FY | -11.61 Million TWD | 98.05% |
| 2022 Q4 | -11.61 Million TWD | -103.45% |
| 2022 Q3 | 336.95 Million TWD | 789.64% |
| 2022 Q1 | -540.24 Million TWD | 9.12% |
| 2021 Q1 | -236.39 Million TWD | -928.44% |
| 2021 FY | -594.47 Million TWD | -2486.26% |
| 2021 Q3 | -136.05 Million TWD | 27.09% |
| 2021 Q4 | -594.47 Million TWD | -336.94% |
| 2021 Q2 | -186.61 Million TWD | 21.06% |
| 2020 Q3 | 329.36 Million TWD | 240.49% |
| 2020 FY | -22.98 Million TWD | 88.07% |
| 2020 Q1 | -143.81 Million TWD | 25.35% |
| 2020 Q4 | -22.98 Million TWD | -106.98% |
| 2020 Q2 | -234.43 Million TWD | -63.01% |
| 2019 Q4 | -192.66 Million TWD | -202.14% |
| 2019 FY | -192.66 Million TWD | -436.68% |
| 2019 Q3 | 188.62 Million TWD | 450.7% |
| 2019 Q2 | -53.78 Million TWD | -142.99% |
| 2019 Q1 | 125.11 Million TWD | 448.53% |
| 2018 FY | -35.89 Million TWD | 16.96% |
| 2018 Q4 | -35.89 Million TWD | -112.6% |
| 2018 Q3 | 284.94 Million TWD | 254510.71% |
| 2018 Q2 | -112 Thousand TWD | 99.73% |
| 2018 Q1 | -42.16 Million TWD | 2.48% |
| 2017 Q2 | -25.26 Million TWD | -155.09% |
| 2017 Q4 | -43.23 Million TWD | -564.96% |
| 2017 FY | -43.23 Million TWD | -21.48% |
| 2017 Q3 | 9.29 Million TWD | 136.8% |
| 2017 Q1 | 45.86 Million TWD | 228.89% |
| 2016 FY | -35.58 Million TWD | -43.76% |
| 2016 Q2 | -285.63 Million TWD | -72.74% |
| 2016 Q3 | -182.04 Million TWD | 36.27% |
| 2016 Q4 | -35.58 Million TWD | 80.45% |
| 2016 Q1 | -165.35 Million TWD | -567.94% |
| 2015 Q1 | 13.36 Million TWD | -87.14% |
| 2015 Q4 | -24.75 Million TWD | 15.38% |
| 2015 FY | -24.75 Million TWD | -123.84% |
| 2015 Q3 | -29.25 Million TWD | 77.62% |
| 2015 Q2 | -130.71 Million TWD | -1078.38% |
| 2014 FY | 103.85 Million TWD | 206.35% |
| 2014 Q4 | 103.85 Million TWD | -38.94% |
| 2014 Q3 | 170.09 Million TWD | 167.22% |
| 2014 Q2 | -253.04 Million TWD | -0.85% |
| 2014 Q1 | -250.91 Million TWD | -156.94% |
| 2013 Q2 | -471.57 Million TWD | -12.17% |
| 2013 Q1 | -420.41 Million TWD | -46.11% |
| 2013 FY | -97.65 Million TWD | 66.06% |
| 2013 Q3 | -234.54 Million TWD | 50.26% |
| 2013 Q4 | -97.65 Million TWD | 58.36% |
| 2012 Q3 | -216.3 Million TWD | 28.38% |
| 2012 Q1 | -217.04 Million TWD | -84.0% |
| 2012 FY | -287.73 Million TWD | -143.93% |
| 2012 Q4 | -287.73 Million TWD | -33.02% |
| 2012 Q2 | -302 Million TWD | -39.14% |
| 2011 Q1 | 172.42 Million TWD | 92.26% |
| 2011 Q4 | -117.95 Million TWD | -199.52% |
| 2011 Q3 | -39.38 Million TWD | -128.85% |
| 2011 Q2 | 136.49 Million TWD | -20.84% |
| 2011 FY | -117.95 Million TWD | -231.53% |
| 2010 FY | 89.68 Million TWD | 121.77% |
| 2010 Q4 | 89.68 Million TWD | 0.0% |
| 2009 FY | -411.97 Million TWD | -10.46% |
| 2008 FY | -372.96 Million TWD | -844.65% |
| 2007 FY | -39.48 Million TWD | -155.6% |
| 2006 FY | 71 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Grape King Bio Ltd | -4.62 Billion TWD | 79.36% |
| Maywufa Company Ltd. | 264.18 Million TWD | 461.392% |
| ScinoPharm Taiwan, Ltd. | -3.32 Billion TWD | 71.246% |
| Lotus Pharmaceutical Co., Ltd. | 9.81 Billion TWD | 109.728% |
| LIWANLI Innovation Co., Ltd. | -244.02 Million TWD | -291.251% |
| YungShin Global Holding Corporation | -247.5 Million TWD | -285.753% |
| PhytoHealth Corporation | -34.64 Million TWD | -2656.107% |
| SCI Pharmtech, Inc. | 100.41 Million TWD | 1050.778% |
| Formosa Laboratories, Inc. | 2.53 Billion TWD | 137.612% |
| PharmaEssentia Corporation | -18.46 Billion TWD | 94.83% |
| Bora Pharmaceuticals Co., LTD. | 1.95 Billion TWD | 148.797% |